Allist Pharmaceuticals

Allist Pharmaceuticals is a pharmaceutical enterprise focused on tumor treatment, aiming to develop first-in-class and best-in-class drugs with independent intellectual property rights. The company operates as a one-stop solution for research, production, and marketing, with its headquarters located in Shanghai's Zhoupu Medical Park. It was founded in March 2004 and officially listed on the Shanghai Stock Exchange's STAR Market in December 2020 under the stock code 688578.

The company's history includes significant milestones such as the approval of Alesitazat (a first-in-class antihypertensive drug) in 2012 and the launch of Fumetinib (Aifusa®) in 2021. It has evolved from a startup to a listed entity, achieving high-tech enterprise status multiple times and becoming a founding member of the 'Pharmaceutical Innovation 100 Alliance' in 2021.

Allist Pharmaceuticals serves patients with unmet clinical needs in the tumor treatment field, specifically targeting EGFR mutation non-small cell lung cancer (NSCLC). Their product pipeline includes Fumetinib, which has been approved for first-line treatment of patients with EGFR exon 19 deletion or exon 21 (L858R) substitution mutations in locally advanced or metastatic NSCLC.

The company is located in Shanghai, with its main R&D center and production base situated in the Zhoupu Medical Park. It also operates a subsidiary, Jiangsu Allist Biopharmaceutical Co., Ltd., established in 2009, which serves as an innovative drug industrialization base with a registered capital of 240 million RMB.

According to the company's website, Allist Pharmaceuticals differentiates itself by focusing on developing both first-in-class and best-in-class drugs with independent intellectual property rights. It aims to create safe, effective, and accessible innovative drugs for the masses, guided by the philosophy of 'Chinese innovation caring for global patients'.

The company's product pipeline includes Fumetinib (Aifusa®), which received approval for a new indication in September 2026 for adjuvant treatment of EGFR mutation NSCLC after surgery. Additionally, the company has introduced a potential global first-in-class ADC to expand into new therapeutic areas.

The company has received numerous accolades, including being named one of the '2020 China Pharmaceutical Innovation Enterprises 100 Strong' and the '2021 China Pharmaceutical Newborn Innovation Power' by the Ministry of Industry and Information Technology. It also won the '2021 Drug Innovation Jishi Award - Annual Drug Innovation Achievement Award' for Aifusa®.

The company collaborates internationally, such as partnering with Belgium's OCTIMET Oncology for Fumetinib combination therapy in 2020 and signing a technology transfer agreement with Fudan University for the PGAM1 inhibitor KH3 project in 2021.

The company's R&D process involves a full lifecycle system including lead drug discovery and optimization, candidate drug evaluation, preclinical and clinical studies, and drug registration declaration. This systematic approach is managed by its Shanghai R&D center located in the Zhoupu Medical Park.

The company's website states that it operates under a non-operating internet drug information service qualification number (沪)-非经营性-2022-0007. It also maintains a public notice for pharmaceutical representatives and a dedicated section for adverse event reporting on its platform.

The company's core values include 'governance as the foundation, innovation leading the way, quality first, and unity of heart and mind.' These principles guide its commitment to environmental responsibility and sustainable development, as outlined in its sustainability policy.

The company's scientific advisory board (SAB) provides guidance on pipeline strategy, project initiation, management, cooperation, clinical development, and team building. This board helps propel the company's innovation and healthy development.

The company's stock code is 688578, and it is listed on the Shanghai Stock Exchange's STAR Market. Its website also provides investor relations information, including quarterly reports and corporate governance announcements.

On Trustburn, Allist Pharmaceuticals has a rating of 4 out of 5 based on 12 reviews.